Orthofix’s Price Target Lowered to $20; 2026 EBITDA Guidance at $95–$98M
Canaccord cut its price target for Orthofix from $24 to $20 and maintained a Buy rating after fourth-quarter performance and 2026 outlook updates. Orthofix forecasts adjusted EBITDA of $95 million to $98 million with positive full-year free cash flow and expects revenue from TRUELOK Elevate, FITBONE systems and a second-half VIRATA launch alongside spine channel simplification, biologics expansion and 7D FLASH Navigation deployment to drive growth.
1. Price Target Reduced After Q4 Update
Canaccord reduced Orthofix’s price target from $24 to $20 while reaffirming a Buy rating. The adjustment followed an update to the company’s financial model reflecting fourth-quarter results and new guidance for 2026.
2. 2026 EBITDA and Cash Flow Guidance
Orthofix projects adjusted EBITDA between $95 million and $98 million for 2026 and anticipates generating positive free cash flow for the full year. This outlook excludes potential impacts from any court settlement.
3. Key Product Launches and Strategic Focus
Management plans full-year revenue contributions from the TRUELOK Elevate System and FITBONE Bone Transport and Trochanteric Lengthening Nails, plus a VIRATA launch in the second half. The company is prioritizing spine channel simplification, biologics expansion and broader adoption of 7D FLASH Navigation to sustain revenue growth, enhance margins and boost cash flow.